Human Papillomavirus Protein E7 (E7) – Pipeline Review, H2 2019

Global Markets Direct’s, 'Human Papillomavirus Protein E7 (E7)- Pipeline Review, H2 2019’, provides in depth analysis on Human Papillomavirus Protein E7 (E7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Women's Health, Infectious Disease and Gastrointestinal under development targeting Human Papillomavirus Protein E7 (E7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)

– The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects

– The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abion Inc

Advaxis Inc

AstraZeneca Plc

Bioleaders Corp

BioNTech SE

Cellid Co Ltd

Cue Biopharma Inc

Etubics Corp

Genexine Inc

Hookipa Pharma Inc

iBio Inc

Immunomic Therapeutics Inc

IMV Inc

Innovene

Inovio Pharmaceuticals Inc

Oxford Vacmedix UK Ltd

Papivax LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

UbiVac LLC

ViciniVax BV

Vir Biotechnology Inc

VLP The Vaccines Company SL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus Protein E7 (E7) - Overview

Human Papillomavirus Protein E7 (E7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development

Abion Inc

Advaxis Inc

AstraZeneca Plc

Bioleaders Corp

BioNTech SE

Cellid Co Ltd

Cue Biopharma Inc

Etubics Corp

Genexine Inc

Hookipa Pharma Inc

iBio Inc

Immunomic Therapeutics Inc

IMV Inc

Innovene

Inovio Pharmaceuticals Inc

Oxford Vacmedix UK Ltd

Papivax LLC

Selecta Biosciences Inc

Touchlight Genetics Ltd

Transgene SA

UbiVac LLC

ViciniVax BV

Vir Biotechnology Inc

VLP The Vaccines Company SL

Human Papillomavirus Protein E7 (E7) - Drug Profiles

(bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABI-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papillomavirus Protein E7 (E7) - Dormant Products

Human Papillomavirus Protein E7 (E7) - Discontinued Products

Human Papillomavirus Protein E7 (E7) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abion Inc, H2 2019

Pipeline by Advaxis Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Bioleaders Corp, H2 2019

Pipeline by BioNTech SE, H2 2019

Pipeline by Cellid Co Ltd, H2 2019

Pipeline by Cue Biopharma Inc, H2 2019

Pipeline by Etubics Corp, H2 2019

Pipeline by Genexine Inc, H2 2019

Pipeline by Hookipa Pharma Inc, H2 2019

Pipeline by iBio Inc, H2 2019

Pipeline by Immunomic Therapeutics Inc, H2 2019

Pipeline by IMV Inc, H2 2019

Pipeline by Innovene, H2 2019

Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Pipeline by Oxford Vacmedix UK Ltd, H2 2019

Pipeline by Papivax LLC, H2 2019

Pipeline by Selecta Biosciences Inc, H2 2019

Pipeline by Touchlight Genetics Ltd, H2 2019

Pipeline by Transgene SA, H2 2019

Pipeline by UbiVac LLC, H2 2019

Pipeline by ViciniVax BV, H2 2019

Pipeline by Vir Biotechnology Inc, H2 2019

Pipeline by VLP The Vaccines Company SL, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports